Puromycin

Identification

Name
Puromycin
Accession Number
DB08437
Type
Small Molecule
Groups
Experimental
Description

Puromycin is an antibiotic that is a protein synthesis inhibitor by inhibiting translation. Puromycin is used in cell biology as selective agent in cell culture systems. It is toxic to prokaryotic and eukaryotic cells.

Structure
Thumb
Synonyms
Not Available
External IDs
3123-L / 3123L / CL-13900 / P-638
Categories
UNII
4A6ZS6Q2CL
CAS number
53-79-2
Weight
Average: 471.5096
Monoisotopic: 471.223017073
Chemical Formula
C22H29N7O5
InChI Key
RXWNCPJZOCPEPQ-NVWDDTSBSA-N
InChI
InChI=1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1
IUPAC Name
(2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)-9H-purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide
SMILES
[H][[email protected]](N)(CC1=CC=C(OC)C=C1)C(=O)N[[email protected]]1([H])[[email protected]@]([H])(CO)O[[email protected]@]([H])(N2C=NC3=C(N=CN=C23)N(C)C)[[email protected]]1([H])O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U60S ribosomal protein L10-likeNot AvailableHuman
U60S ribosomal protein L13aNot AvailableHuman
U60S ribosomal protein L23Not AvailableHuman
U60S ribosomal protein L15Not AvailableHuman
U60S ribosomal protein L19Not AvailableHuman
U60S ribosomal protein L23aNot AvailableHuman
UProbable ribosome biogenesis protein RLP24Not AvailableHuman
U60S ribosomal protein L26-like 1Not AvailableHuman
U60S ribosomal protein L8Not AvailableHuman
U60S ribosomal protein L37Not AvailableHuman
U60S ribosomal protein L3Not AvailableHuman
U60S ribosomal protein L11Not AvailableHuman
ULeucyl/phenylalanyl-tRNA--protein transferaseNot AvailableEscherichia coli (strain K12)
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Puromycin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Puromycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumPuromycin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidPuromycin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Puromycin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Puromycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Puromycin.Approved, Investigational
AmpicillinThe serum concentration of Puromycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Puromycin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumPuromycin may increase the respiratory depressant activities of Atracurium.Experimental, Investigational
Atracurium besylatePuromycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Puromycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Puromycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Puromycin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
BendazacBendazac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Puromycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Puromycin.Approved, Investigational
BevoniumBevonium may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
Botulinum Toxin Type APuromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BPuromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Puromycin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Puromycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Puromycin.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental, Investigational
CarbenicillinThe serum concentration of Puromycin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Puromycin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinPuromycin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Puromycin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
CisatracuriumPuromycin may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylatePuromycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Puromycin.Approved
Clodronic AcidPuromycin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Puromycin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethatePuromycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Puromycin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Puromycin.Approved, Investigational
CyclosporinePuromycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Puromycin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
DecamethoniumPuromycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Puromycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Puromycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Puromycin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Puromycin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Puromycin.Approved, Investigational
Domoic AcidPuromycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chloridePuromycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Puromycin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Puromycin.Approved
EtanerceptEtanercept may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
Etidronic acidPuromycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
exisulindexisulind may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Puromycin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Puromycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Puromycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Puromycin.Approved, Vet Approved
GallaminePuromycin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodidePuromycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Puromycin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
IbandronatePuromycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Puromycin.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Puromycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
MecamylaminePuromycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational, Withdrawn
MetampicillinThe serum concentration of Puromycin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Puromycin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Puromycin.Experimental
MetocurinePuromycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodidePuromycin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Puromycin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumPuromycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Puromycin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinPuromycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Puromycin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Puromycin which could result in a higher serum level.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Puromycin.Approved
OxacillinThe serum concentration of Puromycin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Puromycin.Approved, Vet Approved
PamidronatePuromycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumPuromycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Puromycin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Puromycin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosidePeruvoside may decrease the cardiotoxic activities of Puromycin.Experimental
PhenoxymethylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
PipecuroniumPuromycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Puromycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Puromycin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Puromycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Puromycin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Puromycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Puromycin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Puromycin.Experimental
PTC299PTC299 may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
PyrantelPuromycin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumPuromycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronatePuromycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumPuromycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
SuccinylcholinePuromycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Puromycin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Puromycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Puromycin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Puromycin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Puromycin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronatePuromycin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronatePuromycin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Puromycin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Puromycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Puromycin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidPuromycin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Puromycin.Approved
TranilastTranilast may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Puromycin.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational
TubocurarinePuromycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Puromycin.Approved
VecuroniumPuromycin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Puromycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidPuromycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Puromycin which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C01610
PubChem Compound
439530
PubChem Substance
99444908
ChemSpider
388623
ChEBI
17939
ChEMBL
CHEMBL469912
HET
PUY
PDB Entries
1q7y / 2dpt / 3q3d / 4tva / 5nc5

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)168°C-182°Chttp://www.fermentek.co.il/puromycin.htm
water solubility50mg/mlhttp://www.fermentek.co.il/puromycin.htm
Predicted Properties
PropertyValueSource
Water Solubility1.01 mg/mLALOGPS
logP-0.1ALOGPS
logP-0.3ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)12.35ChemAxon
pKa (Strongest Basic)8.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area160.88 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity122.96 m3·mol-1ChemAxon
Polarizability49.46 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier-0.8691
Caco-2 permeable-0.7728
P-glycoprotein substrateSubstrate0.737
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9243
CYP450 2C9 substrateNon-substrate0.8029
CYP450 2D6 substrateNon-substrate0.8107
CYP450 3A4 substrateSubstrate0.7097
CYP450 1A2 substrateNon-inhibitor0.9058
CYP450 2C9 inhibitorNon-inhibitor0.9133
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9393
CYP450 3A4 inhibitorNon-inhibitor0.724
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8922
Ames testNon AMES toxic0.8607
CarcinogenicityNon-carcinogens0.8681
BiodegradationNot ready biodegradable0.9882
Rat acute toxicity2.2651 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9903
hERG inhibition (predictor II)Non-inhibitor0.5719
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0900300000-347a5da10b8c2c85e6c0
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dj-0900000000-4a2ce92d6902f4ad8eaa
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dj-1900000000-039465e4b89c78bd0b11
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0229-0520900000-37dea53aac093ce884f6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-0910100000-f60802f57acd3074b4c1
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03xs-1900000000-d2fbe55b0731a8cf001f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-0000900000-f82e7526c7ebd78049d9
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03k9-0900500000-0d48aed0c9497b5ab8f3
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0900000000-af8be24075f803a58153
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0900000000-571b6483dc540c02d098
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0900000000-08775f201fb11e558b53
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0000900000-6133e2c60106f3437756
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-05fr-0005900000-a760a4943250cd5405b9
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0809000000-eb619283ee6c689551e3
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0w29-0900000000-ca39c6d95b7bd8fba81b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0900000000-253fadebaa39d03e1cd1
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0a4i-0219000000-6595a051c26ce2ee007b

Taxonomy

Description
This compound belongs to the class of organic compounds known as purine 3'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 3.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Purine 3'-deoxyribonucleosides
Direct Parent
Purine 3'-deoxyribonucleosides
Alternative Parents
Phenylalanine and derivatives / Alpha amino acid amides / 6-alkylaminopurines / Glycosylamines / Pentoses / Amphetamines and derivatives / Phenoxy compounds / Anisoles / Dialkylarylamines / Methoxybenzenes
show 18 more
Substituents
Purine 3'-deoxyribonucleoside / Phenylalanine or derivatives / Alpha-amino acid amide / N-glycosyl compound / Glycosyl compound / 6-alkylaminopurine / 6-aminopurine / Alpha-amino acid or derivatives / Pentose monosaccharide / Amphetamine or derivatives
show 45 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
puromycins (CHEBI:17939)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
May play a role in compensating for the inactivated X-linked gene during spermatogenesis.
Gene Name
RPL10L
Uniprot ID
Q96L21
Uniprot Name
60S ribosomal protein L10-like
Molecular Weight
24518.595 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
Associated with ribosomes but is not required for canonical ribosome function and has extra-ribosomal functions. Component of the GAIT (gamma interferon-activated inhibitor of translation) complex ...
Gene Name
RPL13A
Uniprot ID
P40429
Uniprot Name
60S ribosomal protein L13a
Molecular Weight
23577.11 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
Not Available
Gene Name
RPL23
Uniprot ID
P62829
Uniprot Name
60S ribosomal protein L23
Molecular Weight
14865.335 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
Not Available
Gene Name
RPL15
Uniprot ID
P61313
Uniprot Name
60S ribosomal protein L15
Molecular Weight
24145.945 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
Not Available
Gene Name
RPL19
Uniprot ID
P84098
Uniprot Name
60S ribosomal protein L19
Molecular Weight
23465.775 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
This protein binds to a specific region on the 26S rRNA.
Gene Name
RPL23A
Uniprot ID
P62750
Uniprot Name
60S ribosomal protein L23a
Molecular Weight
17694.885 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
Involved in the biogenesis of the 60S ribosomal subunit. Ensures the docking of GTPBP4/NOG1 to pre-60S particles (By similarity).
Gene Name
RSL24D1
Uniprot ID
Q9UHA3
Uniprot Name
Probable ribosome biogenesis protein RLP24
Molecular Weight
19621.02 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
Not Available
Gene Name
RPL26L1
Uniprot ID
Q9UNX3
Uniprot Name
60S ribosomal protein L26-like 1
Molecular Weight
17256.2 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
Not Available
Gene Name
RPL8
Uniprot ID
P62917
Uniprot Name
60S ribosomal protein L8
Molecular Weight
28024.52 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
Binds to the 23S rRNA.
Gene Name
RPL37
Uniprot ID
P61927
Uniprot Name
60S ribosomal protein L37
Molecular Weight
11077.81 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
The L3 protein is a component of the large subunit of cytoplasmic ribosomes.
Gene Name
RPL3
Uniprot ID
P39023
Uniprot Name
60S ribosomal protein L3
Molecular Weight
46108.72 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Structural constituent of ribosome
Specific Function
Binds to 5S ribosomal RNA (By similarity). Required for rRNA maturation and formation of the 60S ribosomal subunits. Promotes nucleolar location of PML (By similarity).
Gene Name
RPL11
Uniprot ID
P62913
Uniprot Name
60S ribosomal protein L11
Molecular Weight
20252.235 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Transferase activity, transferring amino-acyl groups
Specific Function
Functions in the N-end rule pathway of protein degradation where it conjugates Leu, Phe and, less efficiently, Met from aminoacyl-tRNAs to the N-termini of proteins containing an N-terminal arginin...
Gene Name
aat
Uniprot ID
P0A8P1
Uniprot Name
Leucyl/phenylalanyl-tRNA--protein transferase
Molecular Weight
26618.275 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:31 / Updated on November 09, 2017 04:33